NASH-TAG 2024│來凱醫藥(2105.HK)公佈自研抗肝纖維化抗體最新研究
已建立起全球獨有的肝纖維化藥物發現平台
2024年1月4日 - 來凱醫藥在肝纖維化領域的自主研發取得新進展。在1月4日-6日美國舉行的2024全球NASH-TAG大會上,來凱醫藥(2105.HK)將以壁報形式公佈一個自主研發的靶向激活的肝星狀細胞的雙功能NK-aHSC接合劑藥物發現平台,以及基於該平台技術設計出來的LAE105抗體的抗肝纖維化臨牀前數據。
肝纖維化是導致肝癌或肝功能衰竭的重要原因,而產生肝纖維化的主要因素是激活的肝星狀細胞(aHSC)的積累。來凱早期研發團隊生物高級總監、本次壁報的作者之一張敏華博士介紹,當前針對脂肪肝纖維化的藥物研發多集中在降解肝脂肪,或通過阻斷肝星狀細胞激活過程中的某個信號通路來緩解纖維化。來凱另闢蹊徑,自主開發並建立一個全球領先且獨有的、利用人體自身免疫系統清除aHSC的藥物發現平台。依託這個平台,來凱能夠源源不斷地持續開發抗肝纖維化的抗體。
LAE105就是基於這個獨有平台設計出的一款潛在抗體。“LAE105在結合aHSC表面蛋白後可以招募和激活免疫細胞(如NK細胞),從而利用人體自身的免疫系統來清除aHSC。除了改善肝纖維化,它還可能應用於其它機理相似的纖維化疾病,是一款潛在的first-in-class新藥。”張敏華博士説。
“很高興來凱的臨牀前自主研發又獲新進展。“來凱醫藥首席科學官顧祥巨博士表示:“肝纖維化、代謝和腫瘤是來凱當前聚焦的三大領域,我們擁有紮實的知識底藴、全新的研發理念和獨創的技術平台。目前全球肝纖維化領域尚未有獲批的藥物,希望通過我們的努力加速肝纖維化新藥的突破。”
NASH-TAG是全球最權威的非酒精性脂肪肝和肝纖維化領域學術大會之一,匯聚了臨牀專家、行業學者及業界領袖,聚焦年度重要數據、最新進展和研發趨勢。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.